Latest News and Press Releases

Kneat closed its previously announced bought deal, issuing 7,500,000 shares for gross proceeds to the Company of $35.6 million.

Another global pharmaceutical company selects Kneat to digitize its validation processes.

Kneat filed a final short-form prospectus, which qualifies the distribution of common shares in connection with its previously announced bought deal.

Kneat's Q2 2024 Growth Accelerates YoY, with Revenue up 45%, Annual Recurring Revenue up 60%, Gross Profit up 63%

LIMERICK, Ireland, June 26, 2024 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTC: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that it...

Kneat announces voting results of 2024 Annual General Meeting of shareholders.

Kneat maintains 35% year-over-year revenue growth to surpass $10 million quarterly revenue mark, as annual recurring revenue growth accelerates to 57%.

kneat.com's first quarter 2024 financial results will be published the afternoon of May 8th with an earnings call for investors the morning of May 9th.

Kneat has signed a Master Services Agreement with a global provider of critical care products with over 50,000 employees.

Kneat's Q4 and 2023 financial results show Annual Recurring Revenue up 55% year over year, to $37.4 million, and record gross margin of 72% in Q4.